Double maintains 1 strategies that include CATX - Perspective Therapeutics, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 38.67% | $292.67M | 0% |
CPRJ | 37.34% | $48.38M | 0.69% |
QQA | 34.69% | $187.77M | 0% |
CPSJ | 34.44% | $32.91M | 0.69% |
ARKG | 33.27% | $936.86M | 0.75% |
XBI | 32.87% | $4.76B | 0.35% |
GNOM | 32.49% | $47.13M | 0.5% |
EFAA | 29.94% | $100.03M | 0% |
DFIS | 28.59% | $2.63B | 0.39% |
IBB | 28.44% | $5.61B | 0.45% |
ROBO | 28.42% | $924.80M | 0.95% |
SCZ | 28.12% | $9.03B | 0.4% |
ERTH | 27.60% | $138.98M | 0.67% |
FNDC | 27.42% | $3.16B | 0.39% |
QCLN | 27.07% | $399.59M | 0.59% |
CPSM | 26.90% | $64.66M | 0.69% |
IWC | 26.76% | $797.08M | 0.6% |
ACES | 26.35% | $86.87M | 0.55% |
GRID | 26.26% | $2.02B | 0.57% |
ROBT | 26.25% | $420.42M | 0.65% |
Yahoo
Perspective Therapeutics (CATX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Yahoo
SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. 24th Annual Needham Virtual Healthcare Conference - 1x1s OnlyDate: Monda
Yahoo
On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our next generation targeted radiopharmaceutical technology platformEnrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 30 patients enrolled through end of February 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumorsAchieved first-in-human combi
Finnhub
Perspective Therapeutics Inc: * PERSPECTIVE THERAPEUTICS INC: EXPECT TO HAVE SUFFICIENTFUNDINGINTO LATE 2026Source text:Further company coverage: ...
Yahoo
SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), in patients with histologically confirmed melanoma and positive melanocortin 1 receptor
Finnhub
Perspective Therapeutics Inc: * PERSPECTIVE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSEDWITHVMT01 IN COMBINATION WITH NIVOLUMAB IN A PHASE 1/2A STUDYOF MC1R-POSITIVE METASTATIC...
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -21.27% | $416.76M | 1.43% |
VIXY | -20.84% | $195.31M | 0.85% |
TAIL | -19.91% | $87.65M | 0.59% |
WTMF | -17.93% | $157.25M | 0.65% |
UUP | -10.89% | $325.79M | 0.77% |
TFLO | -10.08% | $6.75B | 0.15% |
UNG | -9.90% | $397.59M | 1.06% |
TPMN | -9.23% | $33.32M | 0.65% |
USDU | -8.87% | $206.96M | 0.5% |
CTA | -8.73% | $978.30M | 0.76% |
AFIF | -5.87% | $135.91M | 1.11% |
ULST | -5.48% | $585.14M | 0.2% |
AGZD | -5.34% | $134.05M | 0.23% |
KRBN | -4.63% | $175.08M | 0.85% |
BAB | -4.08% | $977.85M | 0.28% |
IBTP | -3.97% | $111.57M | 0.07% |
VCRB | -3.63% | $2.55B | 0.1% |
IYK | -3.57% | $1.53B | 0.4% |
TBLL | -3.46% | $2.13B | 0.08% |
JAAA | -3.39% | $21.29B | 0.21% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PHYS | <0.01% | - | - | 0.00% |
CNP | 0.01% | $24.07B | +31.19% | 2.21% |
ANGO | -0.01% | $439.46M | +78.62% | 0.00% |
UNM | -0.02% | $14.66B | +52.74% | 2.06% |
BLCO | 0.02% | $5.06B | -12.98% | 0.00% |
CAH | 0.04% | $33.50B | +25.01% | 1.47% |
HAIN | 0.04% | $365.50M | -42.23% | 0.00% |
POST | -0.05% | $6.54B | +11.31% | 0.00% |
KNOP | 0.05% | $260.66M | +43.40% | 1.46% |
NKE | 0.09% | $96.08B | -28.09% | 2.74% |
SJW | -0.09% | $1.81B | -1.37% | 2.91% |
STZ | -0.10% | $33.02B | -31.55% | 2.23% |
SRE | 0.10% | $47.45B | +2.63% | 3.48% |
WM | 0.11% | $94.32B | +11.47% | 1.30% |
MDT | -0.11% | $113.97B | +4.54% | 3.16% |
CF | 0.14% | $13.29B | -4.06% | 2.51% |
LGTY | 0.15% | $481.08M | +30.17% | 3.08% |
INOD | -0.16% | $1.18B | +431.60% | 0.00% |
EXPD | -0.18% | $16.79B | +3.56% | 1.33% |
NHTC | 0.19% | $59.75M | -26.80% | 15.56% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KURA | 50.35% | $526.52M | -67.94% | 0.00% |
DNTH | 34.20% | $573.76M | -31.91% | 0.00% |
VTYX | 33.26% | $75.40M | -79.54% | 0.00% |
SYRE | 31.80% | $933.38M | -55.31% | 0.00% |
YMAB | 30.94% | $217.05M | -66.71% | 0.00% |
IONS | 30.16% | $4.56B | -34.42% | 0.00% |
ROIV | 30.10% | $7.19B | -12.42% | 0.00% |
RXRX | 29.63% | $2.13B | -40.76% | 0.00% |
SPRY | 29.39% | $1.28B | +38.83% | 0.00% |
IMNM | 29.38% | $583.44M | -68.94% | 0.00% |
SHC | 28.60% | $3.26B | -0.35% | 0.00% |
ADPT | 28.10% | $1.18B | +196.27% | 0.00% |
RCKT | 28.01% | $671.77M | -75.23% | 0.00% |
ATXS | 27.71% | $311.52M | -54.38% | 0.00% |
BEAM | 27.67% | $1.85B | -37.74% | 0.00% |
FATE | 27.48% | $88.24M | -89.02% | 0.00% |
CAAP | 27.46% | $3.02B | +7.89% | 0.00% |
LFUS | 26.64% | $4.86B | -17.85% | 1.62% |
BNT | 26.55% | $10.90B | +33.38% | 0.00% |
COGT | 26.54% | $651.22M | -16.98% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBTM | -0.01% | $310.98M | 0.07% |
SPTL | -0.06% | $11.79B | 0.03% |
IEI | 0.06% | $15.67B | 0.15% |
VGLT | -0.08% | $10.02B | 0.03% |
KMLM | 0.09% | $218.49M | 0.9% |
SPMB | 0.09% | $5.96B | 0.04% |
ICSH | 0.09% | $5.64B | 0.08% |
IBTL | 0.10% | $361.53M | 0.07% |
TLH | 0.11% | $10.21B | 0.15% |
LGOV | 0.11% | $664.16M | 0.67% |
BIL | -0.11% | $41.88B | 0.1356% |
BNDX | -0.14% | $63.13B | 0.07% |
GOVI | 0.17% | $1.07B | 0.15% |
XONE | 0.17% | $631.21M | 0.03% |
XHLF | -0.19% | $1.06B | 0.03% |
ZROZ | -0.20% | $1.61B | 0.15% |
IBTH | -0.20% | $1.51B | 0.07% |
XLP | 0.22% | $16.87B | 0.09% |
JMBS | -0.22% | $5.22B | 0.23% |
EDV | -0.25% | $4.00B | 0.05% |
Current Value
$2.011 Year Return
Current Value
$2.011 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SNOW | -27.18% | $51.42B | +0.58% | 0.00% |
PULM | -13.64% | $22.13M | +234.81% | 0.00% |
CRNC | -13.01% | $363.74M | -42.76% | 0.00% |
CBOE | -12.59% | $23.50B | +25.53% | 1.05% |
AOSL | -12.34% | $754.79M | +12.45% | 0.00% |
SAVA | -10.42% | $67.15M | -93.25% | 0.00% |
EXC | -10.36% | $46.41B | +23.54% | 3.25% |
EW | -9.74% | $42.20B | -22.54% | 0.00% |
WRB | -9.71% | $26.45B | +22.49% | 0.51% |
MRK | -9.45% | $218.76B | -33.33% | 3.60% |
UTI | -9.45% | $1.46B | +81.42% | 0.00% |
CHCT | -9.23% | $513.79M | -28.99% | 10.25% |
VSTS | -8.93% | $1.32B | -47.67% | 1.54% |
TXNM | -8.41% | $4.99B | +44.85% | 2.91% |
LNT | -8.21% | $16.55B | +30.41% | 2.98% |
MCK | -8.11% | $86.92B | +28.41% | 0.38% |
KDP | -7.48% | $47.68B | +13.32% | 2.55% |
MKC | -7.37% | $21.80B | +6.61% | 2.08% |
KO | -7.30% | $306.97B | +19.22% | 2.66% |
UFCS | -7.30% | $750.02M | +35.49% | 2.23% |